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AIM
The overall aim of this project was to develop an evidence-
based CPG for the use of BP-lowering agents in individuals
with CKD. The guideline consists of recommendation
statements, rationale, and a summary of systematically
generated evidence on relevant pre-defined clinical topics.
OVERVIEW OF PROCESS
The development process for the KDIGO Clinical Practice
Guideline for the Management of Blood Pressure in Chronic
Kidney Disease included the following steps:
K Appointing Work Group members and the ERT.
K Discussing process, methods, and results.
K Developing and refining topics.
K Identifying populations, interventions or predictors, and
outcomes of interest.
K Selecting topics for systematic evidence review.
K Standardizing quality assessment methodology.
K Developing and implementing literature-search strategies.
K Screening abstracts and retrieving full-text articles on the
basis of pre-defined eligibility criteria.
K Creating data extraction forms.
K Extracting data and performing critical appraisal of the
literature.
K Grading the methodology and outcomes in individual
studies.
K Tabulating data from individual studies into summary
tables.
K Grading quality of evidence for each outcome across
studies, and assessing the overall quality of evidence
across outcomes with the aid of evidence profiles.
K Grading the strength of recommendations on the basis of
the quality of evidence and other considerations.
K Finalizing guideline recommendations and supporting
rationales.
K Sending the guideline draft for peer review to the KDIGO
Board of Directors in December 2010 and for public
review in July 2011.
K Publishing the final version of the guideline.
The Work Group, KDIGO Co-Chairs, ERT, and KDIGO
support staff met for three 2-day meetings for training in
the guideline development process, topic discussion, and
consensus development.
Commissioning of Work Group and ERT
The KDIGO Co-Chairs appointed the Work Group Co-
Chairs, who then assembled the Work Group of domain
experts, including individuals with expertise in internal
medicine, adult and pediatric nephrology, cardiology,
hypertension, pharmacology, epidemiology, and endocrinol-
ogy. The Tufts Center for Kidney Disease Guideline
Development and Implementation at Tufts Medical Center
in Boston, Massachusetts, USA, was contracted to
conduct systematic evidence review and provide
expertise in guideline development methodology. The ERT
consisted of physician–methodologists with expertise in
nephrology, a project coordinator and manager, and a
research assistant. The ERT instructed and advised Work
Group members in all steps of literature review, critical
literature appraisal, and guideline development. The Work
Group and the ERT collaborated closely throughout the
project.
Defining scope and topics
The Work Group Co-Chairs first defined the overall scope
and goals of the guideline and then drafted a preliminary list
of topics and key clinical questions. The Work Group and
ERT further developed and refined each topic and specified
screening criteria, literature search strategies, and data
extraction forms (Table 5).
Given the lack of robust evidence, the Work Group
decided not to make guideline recommendations for patients
with kidney failure (CKD 5D). The Work Group decided
instead to refer readers to the KDIGO Controversies
Conference paper on this topic.4
Establishing the process for guideline development
The ERT performed literature searches and organized
abstract and article screening. The ERT also coordinated
the methodological and analytical processes and defined
and standardized the methodology for performing
literature searches, data extraction, and summarizing the
evidence. Throughout the project, the ERT offered
suggestions for guideline development and led discussions
on systematic review, literature searches, data extraction,
assessment of quality and applicability of articles,
evidence synthesis, grading of evidence and guideline
recommendations, and consensus development. The Work
Group took the primary role of writing the recommendation
statements and rationale and retained final responsibility for
their content.
The Work Group Co-Chairs prepared the first draft of the
scope of work document as a series of open-ended questions
to be considered by Work Group members. At their first
2-day meeting, members added further questions until the
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initial working document included all topics of interest to the
Work Group. The inclusive, combined set of questions
formed the basis for the deliberation and discussion that
followed. The Work Group strove to ensure that all topics
deemed clinically relevant and worthy of review were
identified and addressed.
Formulating questions of interest
Questions of interest were formulated according to the
PICODD (Population, Intervention, Comparator, Outcome,
study Design and Duration of follow-up) criteria. Details of
the criteria are presented in Table 5.
Ranking of outcomes
The Work Group ranked outcomes of interest on the basis of
their importance for informing clinical decision making
(Table 6). Doubling of SCr level or halving of GFR was
upgraded from ‘high’ to ‘critical’ importance in studies where
the baseline GFR was o60ml/min/1.73m2 (or the SCr was
42mg/dl [4177 mmol/l]), given the known adverse con-
sequences of advanced CKD.
Literature searches and article selection
The Work Group sought to build on the evidence base from
the previous KDOQI Clinical Practice Guidelines on Hyper-
tension and Antihypertensive Agents in Chronic Kidney Disease.1
As the first search for the KDOQI guideline was conducted in
Table 5 | Systematic review topics and screening criteriaa
Diet or lifestyle modification
Population CKD ND: CKD 1–5, non-dialysis, adults and children, with or without hypertension, any type of CKD
Intervention Salt restriction, weight loss, diet, exercise
Comparator Active or control
Outcome Blood pressure, mortality, clinical cardiovascular events, kidney function (categorical or continuous), proteinuria or
urine protein level (categorical or continuous), quality of life, adverse events
Study design RCTs with parallel-group design; cross-over trials
Minimum duration of follow-up 6 weeks for blood pressure, 3 months for proteinuria, 1 year for other outcomes
Minimum N of subjects Z50 per arm
Blood pressure targets
Population CKD ND: CKD 1–5, non-dialysis, adults or children, with or without hypertension, any type of CKDa but
organized by
K DKD (DM and CKD)
K Non-DKD
K CKD in the kidney-transplant recipient (CKD T)
Intervention Lower or low BP target
Comparator Higher or usual BP target
Outcome Mortality, clinical cardiovascular events, kidney function (categorical or continuous), proteinuria or urine protein
level (categorical or continuous), quality of life, adverse events
Study design RCTs with parallel-group design
Minimum duration of follow-up 3 months for proteinuria, 1 year for other outcomes
Minimum N of Subjects Z50 per arm
Agents
Population CKD ND: CKD 1–5, non-dialysis, adults or children, with or without hypertension, any type of CKDa but organized by
K DKD (DM and CKD)
K Non-DKD
K CKD in the kidney-transplant recipient (CKD T)
Intervention Any anti-hypertensive agent (single or in combination, any dose) as well as specific searches for ACE-I, ARB,
aldosterone antagonist, beta-blocker, calcium-channel blocker, diuretic
Comparator Active or placebo
Outcomes Mortality, clinical cardiovascular events, kidney function (categorical or continuous), proteinuria or urine protein
level (categorical or continuous), quality of life, adverse events
Study design RCTs with parallel-group design
Minimum duration of follow-up 3 months for proteinuria, 1 year for other outcomes
Minimum N of Subjects Z50 per arm
ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin-receptor blocker; BP, blood pressure; CKD, chronic kidney disease; CKD ND, non-dialysis-dependent CKD;
CKD T, non–dialysis-dependent CKD with a kidney transplant; DKD, diabetic kidney disease; DM, diabetes mellitus; N, number; RCTs, randomized controlled trials.
aIncludes CKD subgroups from ‘general population’ studies (not exclusively in CKD patients).
Table 6 | Hierarchy of outcomes
Hierarchya Outcomesb
Critical importance Mortality, cardiovascular mortality, cardiovascular
events, kidney failure, composite including clinical
events
High importance Doubling of SCr or halving of GFR, proteinuria
(categorical)
Moderate importance Kidney function (continuous), urine protein level
(continuous)
Importance dependent
on severity
Adverse events: drug discontinuation or dose
decrease, hyperkalemia, early rise of SCr or decrease
of GFR
GFR, glomerular filtration rate; SCr, serum creatinine.
aDoubling of SCr or halving of GFR is of ‘critical’ importance in those studies with
baseline GFR o60ml/min/1.73m2 or SCr 42mg/dl (177 mmol/l).
bThe lists are not meant to reflect outcome ranking for other areas of kidney disease
management. The Work Group acknowledges that not all clinicians, patients or
families, or societies would rank all outcomes the same.
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Table 7 | Relevant systematic reviews and meta-analyses
Title Reference
Databases and cut-off dates of
literature search Use in Work Group deliberation
Topic 1. Low sodium diet or lifestyle modification and change in BP
Lifestyle interventions to reduce raised blood
pressure: a systematic review of randomized
controlled trials
Dickinson et al.53 Cochrane CENTRAL
MEDLINE
Embase
1998–2003
References used to check and
supplement reference list of ERT
systematic review
Systematic review of long term effects of advice
to reduce dietary salt in adults
Hooper et al.62 Cochrane CENTRAL
MEDLINE
Embase
CAB abstracts
CVRCT registry
SIGLE
1982–1998
Further search on sodium
restriction and BP:
Cochrane CENTRAL
MEDLINE
Embase
Up to July 2002
References used to check and
supplement reference list of ERT
systematic review
Topic 2. BP target and kidney outcomes
Progression of chronic kidney disease: the role of
blood pressure control, proteinuria, and
angiotensin-converting enzyme inhibition: a patient
level meta-analysis
Jafar et al.96 MEDLINE
1977–1999
References used to check and
supplement reference list of ERT
systematic review
Topic 3. ACE-I or ARB on CVD and CKD progression
RAS blockade and cardiovascular outcomes in
patients with chronic kidney disease and
proteinuria: a meta-analysis
Balamuthusamy et al.97 OVID
MEDLINE
Embase
1975–2006
References used to check and
supplement reference list of ERT
systematic review
Angiotensin receptor blockers as anti-hypertensive
treatment for patients with diabetes mellitus:
meta-analysis of controlled double-blind
randomized trials
Siebenhofer et al.450 Cochrane CENTRAL
MEDLINE
Embase
Cochrane Controlled Trials
Register
PubMed
DARE
NHSEED
HTA
1992–2002
References used to check and
supplement reference list of ERT
systematic review
Topic 4. ACE-I or ARB on CKD progression
Effect of inhibitors of the renin-angiotensin system
and other anti-hypertensive drugs on renal
outcomes: systematic review and meta-analysis
Casas et al.451 Cochrane CENTRAL
MEDLINE
Embase
1960–Jan. 31, 2005
References used to check and
supplement reference list of ERT
systematic review
Topic 5. ACE-I on CKD progression in CKD without DM
Angiotensin-converting enzyme inhibitors and
progression of non-diabetic renal disease.
A meta-analysis of patient-level data
Jafar et al.141 MEDLINE
May 1977–September 1997
References used to check and
supplement reference list of ERT
systematic review
Topic 6. Anti-hypertensive agents in kidney-transplant recipients
Anti-hypertensives for kidney-transplant recipients:
Systematic review and meta-analysis of randomized
controlled trials
Cross et al.301 Cochrane Renal Group Specialized
Register Cochrane CENTRAL
MEDLINE
Embase
Up to July 1, 2008
References used to check and
supplement reference list of ERT
systematic review
ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin-receptor blocker; BP, blood pressure; CKD, chronic kidney disease; CVD, cardiovascular disease;
DM, diabetes mellitus; ERT, evidence review team; RAS, renin–angiotensin system.
Table 8 | Literature yield
Studies included in
summary tables
Intervention
Abstracts
identified
Articles
retrieved
Studies with
data extracted DKD Non-DKD Transplant
General population
studies in summary tables
Summary
tables
Agents
10, 657 247 55
23 22 6 13 45
Targets 0 8 0 1 3
DKD, diabetic kidney disease.
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July 2002, the search for the current KDIGO Guideline
included publications since January 2002. Search strategies
were developed by the ERTwith input from the Work Group.
The text words or medical subject headings (MeSH) that
were included are provided in the Supplementary Appendix 1
online. Non-human studies and those focusing on dialysis,
pregnancy, neonates, malignant hypertension, acute kidney
injury, or drug pharmacology were excluded.
The MEDLINE, Cochrane Central Register of Controlled
Trials, and Cochrane Database of Systematic Reviews were
searched by the ERT to capture all RCTs on the use of
BP-lowering agents in CKD. The first search was conducted
in November 2009 and was subsequently updated in April
and August of 2010; the final update was done in January
2011. Additional focused searches were conducted to identify
RCTs evaluating lifestyle interventions of salt restriction,
weight loss, and diet and exercise in CKD and to look for
reviews of adverse effects of anti-hypertensive agents. The
ERT relied on Work Group members to identify large, general
population RCTs reporting on subgroup analyses based on
CKD, GFR, or proteinuria status. Additional pertinent
articles were added from the reference lists of JNC 7 and
relevant meta-analyses and systematic reviews (Table 7). The
search yield was also supplemented by articles provided by
Work Group members through February 2012.
A total of 10, 657 citations were initially screened. Journal
articles reporting original data, meta-analyses, and systematic
reviews were selected for evidence review. Editorials, letters,
abstracts, unpublished reports, and articles published in
non–peer-reviewed journals were not included. The Work
Group also decided to exclude publications from journal
supplements because of potential differences in the process of
how they get solicited, selected, reviewed, and edited
compared to peer-reviewed publications. Post hoc analyses
were also excluded, however, after discussion with the Work
Group, it was decided that exception would be made for
post-trial observational follow-up reports from RCTs looking
at BP targets as BP interventions may take longer time to
influence outcomes. These studies were downgraded one
level to designate that they are of lesser quality than the
original RCT. The overall search yield along with the number
of abstracts identified and articles reviewed for each topic are
presented in Table 8.
Data extraction
Data extraction was done by the ERT. The ERT, in
consultation with the Work Group, designed forms to
capture data on design, methodology, sample characteristics,
interventions, comparators, outcomes, results, and limita-
tions of individual studies. Methodology and outcomes were
also systematically graded (see the section on grading below)
and recorded during the data extraction process.
Summary tables
Summary tables were developed for each comparison of
interest (Table 9). Studies included in the evidence base for
the KDOQI Clinical Practice Guidelines on Hypertension and
Antihypertensive Agents in Chronic Kidney Disease1 were also
incorporated if they fulfilled the inclusion criteria for the
current KDIGO Guideline.
Summary tables contain outcomes of interest, relevant
population characteristics, description of intervention and
comparator, results, and quality grading for each outcome.
Categorical and continuous outcomes were summarized
separately. Studies done exclusively in patients of a single
race or ethnicity and studies reporting effect modifications by
baseline urine protein level were annotated. Studies were also
Table 9 |Work products for BP guideline*
Topic
Summary
table of RCTs
Evidence
profile
Diet or lifestyle modification
Exercise +  (single study)
BP targets in CKD without DM
BP target in adults + + (3 studies)
BP target in children +  (single study)
Adverse events of target RCTs + —a
Agents in CKD without DM, non-transplant
ACE-I or ARB versus CCB + + (7 studies)
ACE-I or ARB versus placebo + + (6 studies)
High-dose ACE-I versus low-dose ACE-I + + (2 studies)
ACE-I versus ARB + + (3 studies)
ACE-I versus beta-blocker +  (single study)
High-dose ARB versus low-dose ARB + + (3 studies)
(ACE-I + CCB) versus ACE-I +  (single study)
(ACE-I + CCB) versus CCB +  (single study)
Beta-blocker versus CCB +  (single study)
CCB versus CCB +  (single study)
Central-acting agent versus CCB +  (single study)
Adverse events of agent RCTs + —a
Agents in CKD with DM, non-transplant
Aldosterone antagonist versus placebo +  (single study)
ACE-I or ARB versus CCB + + (7 studies)
ACE-I or ARB versus placebo + + (9 studies)
ACE-I versus ARB + + (3 studies)
ARB versus ARB + + (3 studies)
CCB versus placebo +  (single study)
Direct renin inhibitor versus placebo +  (single study)
Endothelin antagonist versus endothelin
antagonist
+  (single study)
Endothelin antagonist versus placebo +  (single study)
Adverse events of agents in RCTs + —a
Agents in CKD in kidney transplant recipient
ACE-I versus ARB +  (single study)
ARB versus placebo +  (single study)
ACE-I versus CCB + + (2 studies)
CCB versus placebo + + (3 studies)
Adverse events of agent RCTs + —a
CKD subgroups from general population studies
BP target + (1 study)
ACE-I + diuretic versus placebo in DM + (4 studies)
ACE-I or ARB versus control + (5 studies)
ACE + ARB or ARB versus ACE-I + (1 study)
ARB versus CCB + (1 study)
CCB versus control + (2 studies)
ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin-receptor blocker;
BP, blood pressure; CCB, calcium-channel blocker; CKD, chronic kidney disease; DM,
diabetes mellitus; RCTs, randomized controlled trials; +, work product is indicated
for the topic of interest; , work product is not indicated for the topic of interest.
aIncluded in evidence profile for other outcomes.
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categorized by baseline proteinuria status in summary tables
for the CKD with diabetes mellitus topic.
For studies not exclusively examining CKD population,
only those reporting analysis by CKD subgroups were
tabulated. Studies including both diabetes mellitus and
non-diabetes mellitus populations were included in summary
tables for the CKD without diabetes mellitus topic unless
results of subgroup analysis by diabetes mellitus status was
provided.
Work Group members proofed all summary table data
and quality assessments. Summary tables are available at
www.kdigo.org.
Evidence profiles
Evidence profiles were constructed to assess the quality and
record quality grades and descriptions of effect for each
outcome across studies, as well as the quality of overall
evidence and description of net benefits or harms of the
intervention or comparator across all outcomes. These
profiles aim to make the evidence synthesis process
transparent. Decisions in the evidence profiles were based
on data from the primary studies listed in corresponding
summary tables and on judgments of the ERT and the Work
Group. When the body of evidence for a particular
comparison of interest consisted of only one study, the
summary table provided the final level of synthesis and an
evidence profile was not generated. Evidence profiles were
also not created for studies that did not exclusively examine
CKD population. Each evidence profile was initially con-
structed by the ERT and then reviewed, edited, and approved
by the Work Group. The work products created by the ERT
for summarizing the evidence base are listed in Table 9.
Grading of quality of evidence for outcomes of individual
studies
Methodological quality. Methodological quality (internal
validity) refers to the design, conduct, and reporting of
outcomes of a clinical study. A previously devised three-level
classification system for quality assessment was used to grade
the overall study quality and quality of all relevant outcomes in
the study (Table 10). Variations of this system have been used
in most KDOQI and all KDIGO guidelines and have been
recommended for the US Agency for Healthcare Research and
Quality Evidence-based Practice Center program.444
Each study was given an overall quality grade based on its
design, methodology (randomization, allocation, blinding,
definition of outcomes, appropriate use of statistical
methods, etc.), conduct (dropout percentage, outcome
assessment methodologies, etc.) and reporting (internal
consistency, clarity, thoroughness and precision, etc.). Each
reported outcome was then evaluated and given an individual
grade depending on the quality of reporting and methodo-
logical issues specific to that outcome. However, the quality
Table 10 | Classification of study quality
Good
quality
Low risk of bias and no obvious reporting errors; complete
reporting of data. Must be prospective. If study of
intervention, must be RCT.
Fair
quality
Moderate risk of bias, but problems with study or paper are
unlikely to cause major bias. If study of intervention, must be
prospective.
Poor
quality
High risk of bias or cannot exclude possible significant biases.
Poor methods, incomplete data, reporting errors. Prospective
or retrospective.
RCT, randomized controlled trial.
Table 11 | GRADE system for grading quality of evidence
Step 1: Starting grade for quality of
evidence based on study design Step 2: Reduce grade Step 3: Raise grade
Final grade for quality of evidence and
definition
Randomized trials = High
Observational study = Low
Study quality
1 level if serious limitations
2 levels if very serious limitations
Consistency
1 level if important inconsistency
Directness
1 level if some uncertainty
2 levels if major uncertainty
Other
1 level if sparse or imprecise datac
1 level if high probability of reporting bias
Strength of association
+1 level if stronga, no plausible
confounders
+2 levels if very strongb, no major
threats to validity
Other
+1 level if evidence of a
dose–response gradient
+1 level if all residual plausible
confounders would have reduced
the observed effect
High = Further research is unlikely to change
confidence in the estimate of the effect
Moderate = Further research is likely to have
an important impact on confidence in the
estimate of effect, and may change the
estimate
Low = Further research is very likely to have
an important impact on confidence in the
estimate, and may change the estimate
Any other evidence = Very Low
Very Low = Any estimate of effect is very
uncertain
GRADE, Grading of Recommendations Assessment, Development and Evaluation.
aStrong evidence of association is defined as ‘significant relative risk of42 (o0.5)’ based on consistent evidence from two or more observational studies, with no plausible
confounders.
bVery strong evidence of association is defined as ‘significant relative risk of 45 (o0.2)’ based on direct evidence with no major threats to validity.
cSparse if there is only one study or if total N o500. Imprecise if there is a low event rate (0 or 1 event) in either arm or confidence interval spanning a range 41.
Adapted by permission from Macmillan Publishers Ltd, Kidney International. Uhlig K, Macleod A, Craig J et al. Grading evidence and recommendations for clinical
practice guidelines in nephrology. A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2006; 70: 2058–2065;157 accessed
http://www.nature.com/ki/journal/v70/n12/pdf/5001875a.pdf.
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grade of an individual outcome could not exceed the quality
grade for the overall study.
Grading the quality of evidence and the strength of a
guideline recommendation
A structured approach, based on Grading of Recom-
mendations Assessment, Development and Evaluation
(GRADE)156,157,445 and facilitated by the use of evidence
profiles was used to grade the quality of the overall evidence
and the strength of recommendations. For each topic, the
discussion on grading of the quality of the evidence was led
by the ERT, and the discussion regarding the strength of the
recommendations was led by the Work Group Co-Chairs.
The ‘strength of a recommendation’ indicates the extent
to which one can be confident that adherence to the
recommendation will do more good than harm. The ‘quality
of a body of evidence’ refers to the extent to which our
confidence in an estimate of effect is sufficient to support
a particular recommendation.445
Grading the quality of evidence for each outcome across
studies. Following GRADE, the quality of a body of evidence
pertaining to a particular outcome of interest was initially
categorized on the basis of study design. For questions of
interventions, the initial quality grade was ‘High’ if the body
of evidence consisted of RCTs, ‘Low’ if it consisted of
observational studies, and ‘Very Low’ if it consisted of studies
of other study designs. For questions of interventions, the
Work Group decided to use only RCTs. The grade for the
quality of evidence for each intervention–outcome pair was
then lowered if there were serious limitations to the
methodological quality of the aggregate of studies, if there
were important inconsistencies in the results across studies, if
there was uncertainty about the directness of evidence
including limited applicability of the findings to the
population of interest, if the data were imprecise (a low
event rate in either arm or a CI spanning a range 41) or
sparse (only 1 study or total No500), or if there was thought
to be a high likelihood of bias. The final grade for the quality
of the evidence for an intervention–outcome pair could be
one of the following four grades: ‘High’, ‘Moderate’, ‘Low’ or
‘Very Low’ (Table 11).
Grading the overall quality of evidence. The quality of the
overall body of evidence was then determined on the basis of
the quality grades for all outcomes of interest, taking into
Table 14 | KDIGO nomenclature and description for grading recommendations
Implications
Grade* Patients Clinicians Policy
Level 1
‘We recommend’
Most people in your situation would want
the recommended course of action and only
a small proportion would not.
Most patients should receive the
recommended course of action.
The recommendation can be evaluated as a
candidate for developing a policy or a
performance measure.
Level 2
‘We suggest’
The majority of people in your situation
would want the recommended course of
action, but many would not.
Different choices will be appropriate for
different patients. Each patient needs help to
arrive at a management decision consistent
with her or his values and preferences.
The recommendation is likely to require
substantial debate and involvement of
stakeholders before policy can be
determined.
*The additional category ‘Not Graded’ was used, typically, to provide guidance based on common sense or where the topic does not allow adequate application of evidence.
The most common examples include recommendations regarding monitoring intervals, counseling, and referral to other clinical specialists. The ungraded recommendations
are generally written as simple declarative statements, but are not meant to be interpreted as being stronger recommendations than Level 1 or 2 recommendations.
Table 15 |Determinants of strength of recommendation
Factor Comment
Balance between desirable
and undesirable effects
The larger the difference between the
desirable and undesirable effects, the more
likely a strong recommendation is
warranted. The narrower the gradient, the
more likely a weak recommendation is
warranted.
Quality of the evidence The higher the quality of evidence, the
more likely a strong recommendation is
warranted.
Values and preferences The more variability in values and
preferences, or the more uncertainty in
values and preferences, the more likely a
weak recommendation is warranted.
Costs (resource allocation) The higher the costs of an intervention—
that is, the more resources consumed—the
less likely a strong recommendation is
warranted.
Table 13 | Balance of benefits and harms
When there was evidence to determine the balance of medical benefits
and harms of an intervention to a patient, conclusions were categorized
as follows:
K For statistically significant benefit or harm, report as ‘benefit [or
harm] of drug X.’
K For non–statistically significant benefit or harm, report as ‘possible
benefit [or harm] of drug X.’
K In instances where studies are inconsistent, report as ‘possible
benefit [or harm] of drug X.’
K ‘No difference’ can only be reported if a study is not imprecise.
K ‘Insufficient evidence’ is reported if imprecision is a factor.
Table 12 | Final grade for overall quality of evidence
Grade
Quality of
Evidence Meaning
A High We are confident that the true effect lies close to
that of the estimate of the effect.
B Moderate The true effect is likely to be close to the estimate
of the effect, but there is a possibility that it is
substantially different.
C Low The true effect may be substantially different from
the estimate of the effect.
D Very low The estimate of effect is very uncertain, and often
will be far from the truth.
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Table 16 | Existing major guidelines and recommendations on hypertension and anti-hypertensive agents in CKD
Year Group
Target CKD
population
Recommended BP goal
(mm Hg)
Recommended preferred anti-hypertensive
agent(s)
2003 Seventh report of the Joint National Committee on
Prevention, Detection, Evaluation and Treatment of
High Blood Pressure143
http://jama.ama-assn.org/content/289/19/2560.abstract
(accessed July 17, 2012)
Stage 3 CKD,
macroalbuminuria,
kidney-transplant
recipients
o130/80 CKD 3 or macroalbuminuria: ACE-I or ARB in
combination with a diuretic
Kidney-transplant recipients: No particular class
of agents superior
2003 World Health Organization/International Society of Hyper-
tension Statement on Management of Hypertension243
http://www.who.int/cardiovascular_diseases/guidelines/
hypertension_guidelines.pdf
(accessed July 17, 2012)
Type 1 DM with
nephropathy
Type 2 DM with
nephropathy
Non-diabetic
nephropathy
o130/80 Type 1 DM with nephropathy: ACE-I
Type 2 DM with nephropathy: ARB
Non-diabetic nephropathy: ACE-I
2003 European Society of Hypertension–European Society of
Cardiology Guidelines for the Management of Arterial
Hypertension236
http://www.eshonline.org/asset.axd?id=d1381ab0-63ce-
4427-bd8f-f44ef5281c5f&t=633770299529000000
(accessed July 17, 2012)
DM, CKD o130/80 (if urine protein
41 g/d is present, lower
target to lower protein if
possible)
CKD: Diuretic
Type 1 DM with nephropathy: ACE-I
Type 2 DM with nephropathy: ARB
Non-diabetic nephropathy: ACE-I
Proteinuria: ACE-I or ARB
2006 Caring for Australasians with Renal Impairment (CARI)
Guidelines: Prevention of Progression of Kidney Disease
http://www.cari.org.au/ckd_prevent_list_published.php
(accessed August 20, 2012)
DM, CKD CKD in general:
o125/75 (or mean BPo92)
if urine protein 41 g/d
o130/80 (or mean BPo97)
if urine protein 0.25–1 g/d
o130/85 (or mean BPo100)
if urine protein o0.25 g/d
DKD:
o130/85 for patients 450 years
of age
o120/70–75 for those o50 years
of age
Non-DKD:
Regimens including ACE-I more effective than
those not including ACE-I in slowing CKD
progression in non-DKD
Combination therapy of ACE-I and ARB slows
progression of non-DKD more effectively than
either single agent
ACE-I more effective than beta-blockers and
dihydropyridine CCB in slowing progression
of CKD
Beta-blockers more effective than dihydro-
pyridine CCB in slowing CKD progression,
especially in the presence of proteinuria
DKD:
ACE-I for all patients with diabetes and
hypertension
ACE-I for all patients with diabetes and
microalbuminuria or overt nephropathy,
independent of BP and GFR
ARB provides specific renoprotection in
diabetic nephropathy, beyond their
anti-hypertensive benefit
There is insufficient evidence that ACE-I and
ARB combination are of additive specific
benefit in diabetic nephropathy, beyond
additional anti-hypertensive benefit
2008 Canadian Society of Nephrology Guidelines on
Management of CKD238
http://www.cmaj.ca/cgi/content/full/179/11/1154
(accessed July 17, 2012)
DM, CKD o130/80 Non-DKD:
ACE-I or ARB should be included in the
regimen if urine ACR 430mg/mmol
(4300mg/g)
ACE-I, ARB, thiazides, long-acting CCB, or beta-
blockers (for patients older than
60 years) should be included in the regimen if
urine ACR o30mg/mmol (o300mg/g)
DKD:
ACE-I or ARB should be included
in the regimen
2009 Reappraisal of European Guidelines on Hypertension
Management: a European Society of Hypertension
Task Force Document353
http://www.ish.org.il/2009GuidelinesESH.pdf
(accessed July 17, 2012)
DM, CKD Initiate treatment for systolic
BP 4130 and diastolic
BP 485
ACE-I or ARB, but combination therapy with
other agents most likely needed
to control BP
2009 Japanese Society of Hypertension Guidelines for the
Management of Hypertension452
http://www.nature.com/hr/journal/v32/n1/abs/
hr200818a.html
(accessed July 17, 2012)
CKD o130/80
For those with urine protein
Z1 g/d: target o125/75
ACE-I or ARB should be the first choice of
therapy and dose should be titrated by urinary
albumin excretion (o30mg/g for diabetic
nephropathy and o300mg/g for
glomerulonephritis)
For diuretics, thiazides should be used if GFR
Z30ml/min/1.73 m2, and loop diuretics should
be used if GFR o30ml/min/1.73 m2
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account explicit judgments about the relative importance
of each outcome. The resulting four final categories for
the quality of overall evidence were: ‘A’, ‘B’, ‘C’ or ‘D’
(Table 12).
Assessment of the net health benefit across all important
clinical outcomes. The net health benefit was determined on
the basis of the anticipated balance of benefits and harms
across all clinically important outcomes (Table 13). The
assessment of net benefit also involved the judgment of the
Work Group and the ERT.
Grading the strength of the recommendations. The
strength of a recommendation is graded as level 1 or
level 2. Table 14 shows the KDIGO nomenclature for grading
the strength of a recommendation and the implications of
each level for patients, clinicians, and policy makers.
Recommendations can be for or against doing something.
Table 15 shows that the strength of a recommendation is
determined not only by the quality of the evidence but also
by other, often complex judgments regarding the size of the
net medical benefit, values, and preferences, and costs.
Formal decision analyses including cost analysis were not
conducted.
Ungraded statements. This category was designed to allow
the Work Group to issue general advice. Typically an
ungraded statement meets the following criteria: it provides
guidance based on common sense; it provides reminders of
the obvious; and it is not sufficiently specific to allow for
application of evidence to the issue and therefore it is not
based on systematic evidence review. Common examples
include recommendations about frequency of testing, referral
to specialists, and routine medical care. We strove to
minimize the use of ungraded recommendations.
This grading scheme, with two levels for the strength
of a recommendation together with four levels of grading
the quality of the evidence, as well as the option of an
ungraded statement for general guidance, was adopted by
the KDIGO Board in December 2008. The Work Group took
on the primary role of writing the recommendations
and rationale and retained final responsibility for the
content of the guideline statements and the accompanying
narrative. The ERT reviewed draft recommendations and
grades for consistency with the conclusions of the evidence
review.
Format for guideline recommendations. Each chapter
contains one or more specific recommendations. Within
each recommendation, the strength of recommendation is
indicated as level 1 or level 2 and the quality of the
supporting evidence is shown as A, B, C, or D. The recom-
mendation statements and grades are followed by a brief
background with relevant definitions of terms and then the
rationale starting with a ‘chain of logic,’ which consists of
declarative sentences summarizing the key points of the
Table 16 | Continued
Year Group
Target CKD
population
Recommended BP goal
(mm Hg)
Recommended preferred anti-hypertensive
agent(s)
2011 The Renal Association (UK) CKD Guidelines396
http://www.renal.org/Clinical/GuidelinesSection/
Detection-Monitoring-and-Care-of-Patients-with-CKD.aspx
(accessed August 28, 2012)
CKD For the majority, systolic
BP: o140mmHg (target range
120–139mmHg)
and diastolic BP: o90mmHg for
the majority
ACE-I or ARB
For those with DM or proteinuria
X1g/24 h, systolic BP:
o130mmHg (target range
120–129 mmHg) and diastolic BP:
o80 mm Hg unless the risks are
considered to outweigh
the potential benefits
Antihypertensive therapy should
be individualized and lowering the
systolic blood pressure to
o120 mm Hg should be avoided
2012 Canadian Hypertension Education Program
Recommendations
http://www.hypertension.ca/chep-recommendations
(accessed August 20, 2012)
Non-DKD
and DKD
CKD in general: o140/90
DKD: o130/80
Non-DKD:
ACE-I or ARB (if ACE-I intolerant) as a first
choice agent if urine ACR 430mg/mmol
(4300mg/g) or urine protein 4500mg/24 h
DKD:
For patients with persistent microalbuminuria
(urine ACR 42mg/mmol [420mg/g] in men
and 42.8mg/mmol [428mg/g] in women),
ACE-I or or ARB is recommended as initial
therapy
2012 American Diabetes Association453
http://care.diabetesjournals.org/content/35/Supplement_1/
S11.full.pdf (accessed August 20, 2012)
DM with
microalbuminuria
or overt
nephropathy
o130/80 ACE-I or ARB should be considered
for patients with microalbuminaria or
macroalbuminaria. If ACE-I or ARB is not
tolerated, then diuretics, CCBs, and beta-
blockers should be considered
ACE-I, angiotensin-converting enzyme inhibitor; ACR, albumin/creatinine ratio; ARB, angiotensin-receptor blocker; BP, blood pressure; CCB, calcium-channel blocker;
CKD, chronic kidney disease; DKD, diabetic kidney disease; DM, diabetes mellitus; GFR, glomerular filtration rate.
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Table 17 | The Conference on Guideline Standardization (COGS) checklist for reporting clinical practice guidelines
Topic Description
Discussed in KDIGO Management of Blood Pressure in Chronic
Kidney Disease Guideline
1. Overview material Provide a structured abstract that includes the guideline’s
release date, status (original, revised, updated), and print
and electronic sources.
Abstract and Methods for Guideline Development.
2. Focus Describe the primary disease/condition and intervention/
service/technology that the guideline addresses. Indicate any
alternative preventative, diagnostic or therapeutic
interventions that were considered during development.
Management of blood pressure and the use of anti-hypertensive
agents in adults and children with CKD ND, including those with
kidney transplants.
3. Goal Describe the goal that following the guideline is expected
to achieve, including the rationale for development of a
guideline on this topic.
This clinical practice guideline is intended to assist the practitioner
caring for patients with non-dialysis CKD and hypertension and to
prevent deaths, CVD events, and progression to kidney failure while
optimizing patients’ quality of life.
4. User/setting Describe the intended users of the guideline (e.g., provider
types, patients) and the settings in which the guideline is
intended to be used.
Providers: Nephrologists (adult and pediatric), Internists, and
Pediatricians.
Patients: Adults and children with CKD at risk for hypertension.
Policy Makers: Those in related health fields.
5. Target population Describe the patient population eligible for guideline
recommendations and list any exclusion criteria.
Adults and children with CKD, not on dialysis; kidney transplant
recipients.
6. Developer Identify the organization(s) responsible for guideline
development and the names/credentials/potential conflicts
of interest of individuals involved in the guideline’s
development.
Organization: KDIGO
Names/credentials/potential conflicts of interest of individuals
involved in the guideline’s development are disclosed in the
Biographic and Disclosure Information.
7. Funding source/sponsor Identify the funding source/sponsor and describe its role in
developing and/or reporting the guideline. Disclose potential
conflict of interest.
KDIGO is supported by the following consortium of sponsors: Abbott,
Amgen, Bayer Schering Pharma, Belo Foundation, Bristol-Myers
Squibb, Chugai Pharmaceutical, Coca-Cola Company, Dole Food
Company, Fresenius Medical Care, Genzyme, Hoffmann-LaRoche, JC
Penney, Kyowa Hakko Kirin, NATCO—The Organization for Transplant
Professionals, NKF-Board of Directors, Novartis, Pharmacosmos,
PUMC Pharmaceutical, Robert and Jane Cizik Foundation, Shire,
Takeda Pharmaceutical, Transwestern Commercial Services, Vifor
Pharma, and Wyeth. No funding is accepted for the development or
reporting of specific guidelines.
All stakeholders could participate in open review.
8. Evidence collection Describe the methods used to search the scientific literature,
including the range of dates and databases searched, and
criteria applied to filter the retrieved evidence.
Topics were triaged either to a) systematic review, b) systematic
search followed by narrative summary, or c) narrative summary. For
systematic reviews on treatment with different anti-hypertensive
agents or to different BP targets, we searched for RCTs in MEDLINE,
Cochrane Central Registry for trials, and Cochrane database of
systematic reviews. Screening criteria are outlined in the Methods for
Guideline Development chapter. The search was updated through
January 2011 and supplemented by articles identified by Work Group
members through February 2012. We also searched for pertinent
existing guidelines and systematic reviews.
9. Recommendation
grading criteria
Describe the criteria used to rate the quality of evidence that
supports the recommendations and the system for
describing the strength of the recommendations.
Recommendation strength communicates the importance of
adherence to a recommendation and is based on both the
quality of the evidence and the magnitude of anticipated
benefits and harms.
Quality of individual studies was graded in a three-tiered grading
system (see Table 10). Quality of evidence and strength of
recommendations were graded following the GRADE approach
(Tables 12 and 14).
The Work Group could provide general guidance in unngraded
statements.
10. Method for synthesizing
evidence
Describe how evidence was used to create
recommendations, e.g., evidence tables, meta-analysis,
decision analysis.
For systematic review topics, summary tables and evidence profiles
were generated. For recommendations on treatment interventions,
the steps outlined by GRADE were followed.
11. Prerelease review Describe how the guideline developer reviewed and/or
tested the guidelines prior to release.
The guideline had undergone internal review at the 2010 KDIGO
Board of Directors meeting and external public review in July 2011.
Public review comments were compiled and fed back to the Work
Group, which considered comments in its revision of the guideline.
12. Update plan State whether or not there is a plan to update the guideline
and, if applicable, an expiration date for this version of the
guideline.
There is no date set for updating. The need for updating of the
guideline will depend on the publication of new evidence that would
change the quality of the evidence or the estimates for the benefits
and harms. Results from registered ongoing studies and other
publications will be reviewed periodically to evaluate their potential
to impact on the recommendations in this guideline.
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evidence base and the judgments supporting the recommen-
dation. This is followed by a narrative in support of the
rationale. In relevant sections, research recommendations
suggest future research to resolve current uncertainties.
Comparison with other guidelines
We tabulated recommendations from other key English-
language guidelines pertinent to the use of blood-pressure–
lowering agents in individuals with CKD (Table 16). This
served to inform topic selection and scope. Also, after
recommendations had been drafted, the Work Group
reviewed them in the context of the existing guideline
recommendations to avoid unnecessary or unwarranted
discrepancies.
Limitations of approach
Although the literature searches were intended to be
comprehensive, they were not exhaustive. MEDLINE was
the only database searched. Hand searches of journals were
not performed, and review articles and textbook chapters
were not systematically searched. However, important studies
known to domain experts that were missed by the electronic
literature searches were added to retrieved articles and
reviewed by the Work Group.
Review of guideline development process
Several tools and checklists have been developed to assess the
quality of the methodological process for guideline develop-
ment. These include the Appraisal of Guidelines for Research
and Evaluation (AGREE) criteria,446 the Conference on
Guideline Standardization (COGS) checklist,447 and the
Institute of Medicine’s recent Standards for Systematic
Reviews,448 and Clinical Practice Guideines We Can Trust.449
Table 17 and Supplementary Appdenix 2 online show,
respectively, the COGS criteria and the Institute of Medicine
standards, and how each one of them is addressed in this
Guideline.
SUPPLEMENTARY MATERIAL
Supplementary Appendix 1. Online search strategies.
Supplementary Appendix 2. Concurrence with Institute of Medicine
standards for systematic reviews and for guidelines.
Supplementary material is linked to the online version of the paper at
http://www.kdigo.org/clinical_practice_guidelines/bp.php
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Topic Description
Discussed in KDIGO Management of Blood Pressure in Chronic
Kidney Disease Guideline
13. Definitions Define unfamiliar terms and those critical to correct
application of the guideline that might be subject to
misinterpretation.
Abbreviations and Acronyms.
14. Recommendations and
rationale
State the recommended action precisely and the specific
circumstances under which to perform it. Justify each
recommendation by describing the linkage between the
recommendation and its supporting evidence. Indicate the
quality of evidence and the recommendation strength, based
on the criteria described in Topic 9.
Each guideline chapter contains recommendations for blood
pressure management of CKD patients. Each recommendation builds
on a supporting rationale with evidence tables if available. The
strength of the recommendation and the quality of evidence are
provided in parenthesis within each recommendation.
15. Potential benefits and
harms
Describe anticipated benefits and potential risks associated
with implementation of guideline recommendations.
The benefits and harm for each comparison of interventions are
provided in summary tables and summarized in evidence profiles.
The estimated balance between potential benefits and harm was
considered when formulating the recommendations.
16. Patient preferences Describe the role of patient preferences when a
recommendation involves a substantial element of personal
choice or values.
Many recommendations are level 2 or ‘‘discretionary,’’ which
indicates a greater need to help each patient arrive at a management
decision consistent with her or his values and preferences.
17. Algorithm Provide (when appropriate) a graphical description of the
stages and decisions in clinical care described by the
guideline.
No overall algorithm.
18. Implementation
considerations
Describe anticipated barriers to application of the
recommendations. Provide reference to any auxiliary
documents for providers or patients that are intended to
facilitate implementation. Suggest review criteria for
measuring changes in care when the guideline is
implemented.
These recommendations are global. Review criteria were not
suggested because implementation with prioritization and
development of review criteria have to proceed locally. Furthermore,
most recommendations are discretionary, requiring substantial
discussion among stakeholders before they can be adopted as review
criteria.
Suggestions were provided for future research.
BP, blood pressure; CKD, chronic kidney disease; CKD ND, non–dialysis-dependent CKD; CVD, cardiovascular disease; GRADE, Grading of Recommendations Assessment,
Development and Evaluation; KDIGO, Kidney Disease: Improving Global Outcomes; RCT, randomized controlled trial.
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